$HTBX why people expect the readout of hs-110 on 29th? It seems like it’s already presented positive a few months ago. Our HS-110 Phase 2, multicenter clinical trial is evaluating the safety and efficacy of HS-110 in combination with Bristol-Myers Squibb’s checkpoint inhibitor, nivolumab (Opdivo®) or Merck’s checkpoint inhibito pembrolizumab (Keytruda®). The enrollment for this trial has completed with approximately 120 patients. Positive interim results have been presented at leading medical conferences including American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR) and Society for Immunotherapy of Cancer (SITC).